Overview

A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers

Status:
Completed

Trial end date:
2018-03-26

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate dose proportionality and pharmacokinetics for three different dose levels of eliglustat after single and repeated administration.

Phase:

Phase 1

Details

Lead Sponsor:

Sanofi

Treatments:

Eliglustat